Brain Metastasis clinical trials

Explore recruiting brain metastasis clinical trials.

Recruiting brain metastasis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Brain Metastasis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02D

Hungary, Poland, Greece, Spain, Italy, France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Evaluation of 68GaNOTA-Anti-HER2 VHH1 uptake in brain metastasis of cancer patients

Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

Single arm phase II study of the efficacy and safety of the combination of Trastuzumab plus TUCAtinib plus viNorelbine in patients with HER2-positive non-resectable locally advanced or metastatic breast cancer “TrasTUCAN Study”

Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A phase II study assessing safety and efficacy of REPotrectinib in ROS1-positive non-small cell lung cancer patients with active brain mEtastasis (The REPOSE study)

Germany, Spain, Austria

Therapeutic exploratory (Phase II) EU CTIS Study details

Nivolumab plus Ipilimumab plus two cycles of platinum-based chemotherapy as first line treatment for stage IV/recurrent non-small cell lung cancer (NSCLC) patients with synchronous Brain metastases_NIVIPI-Brain

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

BEPCOME-MB: Phase 2, randomised trial testing the addition of upfront stereotactic radiosurgery to binimetinib, encorafenib plus pembrolizumab in comparison with binimetinib, encorafenib plus pembrolizumab alone in patients with BRAFV600 mutationpositive melanoma with brain metastasis

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Brain Metastasis trials by city

Brain Metastasis in Toronto Brain Metastasis in Vancouver Brain Metastasis in Montreal Brain Metastasis in Calgary Brain Metastasis in Edmonton Brain Metastasis in Ottawa Brain Metastasis in Winnipeg Brain Metastasis in Quebec City Brain Metastasis in Hamilton Brain Metastasis in Kitchener Brain Metastasis in London Brain Metastasis in Halifax Brain Metastasis in New York Brain Metastasis in Los Angeles Brain Metastasis in Chicago Brain Metastasis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease